An in‐depth analysis of COVID‐19 treatment: Present situation and prospects
Archiv der Pharmazie · 2024
DOI: 10.1002/ardp.202400307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2024. Verfasst von Md Ariful Islam und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, COVID-19, Drug Repositioning. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 142 Literaturangaben. Gefördert von: All India Council for Technical Education (AICTE), New Delhi, India is gratefully acknowledged (8-21/FDC/RPS (NER)/POLICY-1/2020-21), Department of Health Research (DHR), New Delhi, India, Grant/Award Number R.12012/06/2023-h.
Abstract (Originalsprache)
Coronavirus disease 2019 (COVID‐19) the most contagious infection caused by the unique type of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), produced a global pandemic that wreaked havoc on the health‐care system, resulting in high morbidity and mortality. Several methods were implemented to tackle the virus, including the repurposing of existing medications and the development of vaccinations. The purpose of this article is to provide a complete summary of the current state and future possibilities for COVID‐19 therapies. We describe the many treatment classes, such as antivirals, immunomodulators, and monoclonal antibodies, that have been repurposed or developed to treat COVID‐19. We also looked at the clinical evidence for these treatments, including findings from observational studies and randomized‐controlled clinical trials, and highlighted the problems and limitations of the available evidence. Furthermore, we reviewed existing clinical trials and prospective COVID‐19 therapeutic options, such as novel medication candidates and combination therapies. Finally, we discussed the long‐term consequences of COVID‐19 and the importance of ongoing research into the development of viable treatments. This review will help physicians, researchers, and policymakers to understand the prevention and mitigation of COVID‐19.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India.
- Department of Petroleum Engineering, DUIET, Dibrugarh, University, Assam, India.
- Drug Design & Discovery Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, Uttar Pradesh, India.
Förderung
- All India Council for Technical Education (AICTE), New Delhi, India is gratefully acknowledged (8-21/FDC/RPS (NER)/POLICY-1/2020-21)
- Department of Health Research (DHR), New Delhi, India, Grant/Award Number R.12012/06/2023-h
Zitieren
APA
Islam, M. A., Pathak, K., Saikia, R., Pramanik, P., Das, A., Talukdar, P., Shakya, A., Ghosh, S. K., Singh, U. P., & Bhat, H. R. (2024). An in‐depth analysis of COVID‐19 treatment: Present situation and prospects. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202400307
Vancouver
Islam MA, Pathak K, Saikia R, Pramanik P, Das A, Talukdar P, et al. An in‐depth analysis of COVID‐19 treatment: Present situation and prospects. Archiv der Pharmazie. 2024. doi:10.1002/ardp.202400307
BibTeX
@article{Islam2024,
author = {Islam, Md Ariful and Pathak, Kalyani and Saikia, Riya and Pramanik, Pallab and Das, Aparoop and Talukdar, Prasenjit and Shakya, Anshul and Ghosh, Surajit Kumar and Singh, Udaya Pratap and Bhat, Hans Raj},
title = {An in‐depth analysis of COVID‐19 treatment: Present situation and prospects},
journal = {Archiv der Pharmazie},
year = {2024},
doi = {10.1002/ardp.202400307}
}
EUVIMED